Welcome to our dedicated page for OKYO PHARMA news (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO PHARMA stock.
OKYO Pharma Limited develops investigational ophthalmic therapies for neuropathic corneal pain and inflammatory eye diseases. The company’s lead candidate, urcosimod, formerly OK-101, is described as a lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, with development centered on ocular pain and inflammation.
Recurring company updates cover urcosimod clinical data, patient-reported outcomes from a completed Phase 2 study in neuropathic corneal pain, FDA IND and Fast Track status for the NCP program, scientific advisory and ophthalmology-conference presentations, ordinary-share ownership disclosures, and purchases of Nasdaq-listed ordinary shares by company insiders.
OKYO Pharma (OKYO) will present at the Ophthalmology Futures European Forum on September 10 and ESCRS iNovation Day on September 11, 2026, in London.
The company aims to engage clinicians, industry leaders, and investors as it advances urcosimod, its lead asset for neuropathic corneal pain (NCP), through its global Phase 3 pivotal NEPTUNE trial. OKYO reports recent positive feedback from a U.S. FDA Type D meeting, which it says validated the regulatory and clinical path forward for urcosimod, and notes an Annual Report filing reflecting a strengthened cash position. OKYO plans to initiate a global Phase 3 pivotal trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for NCP.
OKYO Pharma (OKYO) will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 8:35 AM ET, featuring Chief Medical Officer Flavio Mantelli and Chief Development Officer Gary Jacob, moderated by Cantor Fitzgerald’s Eric Fitzgerald.
The company will also be available for one-on-one meetings during the event. OKYO links this participation to recent positive FDA Type D meeting feedback that validated the regulatory and clinical path for its NCP candidate urcosimod, a strengthened cash position disclosed in its latest Annual Report, and plans to start a global Phase 3 pivotal trial in the second half of the year with about 111 patients on a single-dose regimen.
OKYO Pharma (Nasdaq: OKYO) reported that Chief Scientific Officer Raj Patil, PhD, has increased his personal stake in the company by purchasing 3,363 ordinary shares on Nasdaq at $1.49 per share, bringing his total holding to 20,030 ordinary shares.
OKYO Pharma is a clinical-stage biopharmaceutical company developing investigational therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. According to the company, it plans to initiate a global Phase 3 pivotal trial in the second half of this year, enrolling about 111 patients to evaluate a single-dose regimen of urcosimod for NCP.
OKYO Pharma (Nasdaq: OKYO) will participate in the virtual BTIG Biotechnology Conference 2026 on July 28-29, 2026. Company representatives will include CEO Robert J. Dempsey, CFO Keeren Shah, and CMO Flavio Mantelli.
The company is a clinical-stage biopharmaceutical developer of therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. According to OKYO Pharma, it plans to initiate a global Phase 3 pivotal trial in the second half of this year, enrolling about 111 patients to evaluate a single-dose regimen of urcosimod for NCP.
The conference will feature virtual 1:1 meetings, which can be scheduled through a BTIG representative. Additional corporate and contact information is available on OKYO Pharma’s website and through its business development and investor relations contact.
OKYO Pharma (Nasdaq: OKYO) reported that Non-Executive Director John Brancaccio purchased 5,000 ordinary shares on Nasdaq at $1.48 per share, increasing his total holding to 35,201 shares. The company is a clinical-stage biopharmaceutical developer of investigational therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases, with its ordinary shares listed on the Nasdaq Capital Market.
According to OKYO Pharma, the company plans to initiate a global Phase 3 pivotal clinical trial of urcosimod for NCP in the second half of this year, targeting enrollment of approximately 111 patients to assess a single-dose regimen.
OKYO Pharma (Nasdaq: OKYO), a clinical-stage biopharmaceutical company focused on neuropathic corneal pain (NCP) and anterior segment eye diseases, announced that Chief Executive Officer Robert J. Dempsey purchased 15,000 ordinary shares of the company on Nasdaq at $1.54 per share.
OKYO’s ordinary shares trade on the Nasdaq Capital Market. According to OKYO Pharma, the company plans to initiate a global Phase 3 pivotal clinical trial of urcosimod for NCP in the second half of this year, targeting enrollment of approximately 111 patients in a single-dose regimen study.
OKYO Pharma (Nasdaq: OKYO) reported that Chief Development Officer and Director Gary S. Jacob, PhD, purchased 3,500 ordinary shares on Nasdaq at $1.40 per share, increasing his total holding to 112,420 ordinary shares.
The company is a clinical-stage biopharmaceutical developer of therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases and plans to start a global Phase 3 pivotal trial in the second half of this year, enrolling about 111 patients to evaluate a single-dose regimen of urcosimod for NCP.
OKYO Pharma (Nasdaq: OKYO) reported that its Chief Medical Officer, Flavio Mantelli, MD, PhD, purchased 20,000 ordinary shares of the company on Nasdaq at $1.40 per share. OKYO is a clinical-stage biopharmaceutical company focused on neuropathic corneal pain (NCP) and anterior segment eye diseases, with its ordinary shares traded on the Nasdaq Capital Market.
According to OKYO Pharma, the company plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.
OKYO Pharma (Nasdaq: OKYO) will present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026 at 12:30 PM ET. CEO Robert J. Dempsey and CMO Flavio Mantelli will present virtually. OKYO is developing urcosimod for neuropathic corneal pain and plans a global Phase 3 trial.
OKYO Pharma (Nasdaq: OKYO) reported that Chairman Gabriele Cerrone, via Panetta Partners, purchased 25,000 ordinary shares at $1.40 per share. According to OKYO Pharma, this increases his total holding to 10,851,416 shares, representing 20.51% of the company’s issued share capital.
The clinical-stage biopharmaceutical company focuses on therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. OKYO plans to start a global Phase 3 pivotal trial in the second half of this year, enrolling about 111 patients to evaluate a single-dose regimen of urcosimod for NCP.